Anthropic adds Ben Bernanke to Long-Term Benefit Trust

Investing.com -- Anthropic appointed Ben Bernanke to its Long-Term Benefit Trust on Thursday. Bernanke, a Distinguished Fellow at the Brookings Institution and former Federal Reserve Chair, joins the independent body tasked with holding the AI company to its mission of responsible advanced AI development.

Bernanke served as Federal Reserve Chair from 2006 to 2014, leading the central bank during the 2008 global financial crisis and subsequent recovery. He spent over 20 years as an academic economist, primarily at Princeton, where he chaired the economics department and conducted research on the Great Depression and banking’s role in financial crises. He received the Nobel Prize in Economic Sciences in 2022 for this work.

"The potential of artificial intelligence is enormous, and so is the range of outcomes. How that potential plays out will depend, in part, on the institutions we build around it," Bernanke said. "Anthropic has created a unique governance structure to try to ensure that the long-run benefits of AI for humanity far outweigh the risks."

Daniela Amodei, Cofounder and President of Anthropic, said Bernanke’s career spans studying economic reactions to disruptive moments and steering the world’s largest economy through such periods. She said his judgment will help the company anticipate and respond to how advanced AI affects workforces and economies globally.

Anthropic operates as a Public Benefit Corporation, balancing commercial success with social and public good. The Long-Term Benefit Trust provides oversight on how Anthropic develops and deploys AI. Trustees hold no equity in Anthropic, receive no profits, and are compensated only for their time and service. Existing Trustees select new members in consultation with the company.

The Trust holds authority to appoint Anthropic board members and advises leadership on decisions involving AI risks and societal impacts. Bernanke joins Neil Buddy Shah, Richard Fontaine, and Mariano-Florentino Cuéllar on the Trust.

You May Also Be Interested In

• Jamie Dimon faces Warren scrutiny over reported Epstein-linked lobbying advice
• Citi sees AppLovin US growth as 'solid'
• Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA